[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fo8ROZW_-x9EcNPTLGA5yyEjLdbtYPxtpyB5DWX1_B0I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":51,"rows":58},"National Human Genome Research Institute (NHGRI)",[4],203,false,37,0,243408,8,181,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Diabetes",9,{"name":18,"count":19},"Healthy Volunteers",7,{"name":21,"count":22},"Breast Cancer",6,{"name":24,"count":25},"Cancer",5,{"name":27,"count":25},"Genetic Disease",{"name":29,"count":30},"Prostate Cancer",4,{"name":32,"count":30},"Genetics",{"name":34,"count":30},"Pregnancy",[36,41,46],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04316546","MK-7075 (Miransertib) in Proteus Syndrome","2026-07-01","MK-7075",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06664814","An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis","2027-11-30","ManNAc",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03952637","A Phase 1\u002F2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","2028-01-01","AAV9-GLB1",[52,53,54,55,56,57],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[59,106,139,177,195,213,231,249,273,299,324,342,375,393,411,429,447,474,498,522,546,570,600,618,645,670,694,712,739,757,775],{"intervention":45,"totalTrials":60,"cells":61},3,{"EARLY_PHASE1":62,"PHASE1":64,"PHASE2":78,"PHASE3":100,"PHASE4":102,"NA":104},{"trials":63,"activeCount":9},[],{"trials":65,"activeCount":9},[66],{"nctId":67,"briefTitle":68,"status":69,"phases":70,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":77},"NCT01634750","Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)","COMPLETED",[53],"2013-05-29","2012-09-11",26,[75,76],"Hereditary Inclusion Body Myopathy (HIBM)","GNE Myopathy",[45],{"trials":79,"activeCount":99,"soonestReadout":44},[80,90],{"nctId":81,"briefTitle":82,"status":69,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NCT02346461","An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy",[54],"2017-12-30","2018-11-15","2015-02-05",12,[76],[45,45],{"nctId":42,"briefTitle":43,"status":91,"phases":92,"primaryCompletion":44,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"RECRUITING",[54],"2027-12-01","2026-06-07",30,[97],"Focal Segmental Glomerulosclerosis",[45],1,{"trials":101,"activeCount":9},[],{"trials":103,"activeCount":9},[],{"trials":105,"activeCount":9},[],{"intervention":40,"totalTrials":107,"cells":108},2,{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":123,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":110,"activeCount":9},[],{"trials":112,"activeCount":9},[113],{"nctId":114,"briefTitle":115,"status":69,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":22,"conditions":120,"interventions":122},"NCT02594215","Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome",[53],"2017-12-31","2022-06-24","2015-11-16",[121],"Proteus Syndrome",[40],{"trials":124,"activeCount":99,"soonestReadout":39},[125],{"nctId":37,"briefTitle":38,"status":126,"phases":127,"primaryCompletion":39,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"ACTIVE_NOT_RECRUITING",[54],"2028-07-01","2022-05-20",38,[121],[40],{"trials":134,"activeCount":9},[],{"trials":136,"activeCount":9},[],{"trials":138,"activeCount":9},[],{"intervention":140,"totalTrials":107,"cells":141},"Sirolimus",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":143,"activeCount":9},[],{"trials":145,"activeCount":9},[],{"trials":147,"activeCount":99,"soonestReadout":49},[148,159],{"nctId":149,"briefTitle":150,"status":69,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":158},"NCT02428296","Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation",[54],"2018-02-14","2015-04-23",39,[156,157,32],"PIK3CA-Related Overgrowth Spectrum (PROS)","Growth Disorder",[140],{"nctId":47,"briefTitle":48,"status":91,"phases":160,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":163,"interventions":167},[53,54],"2019-08-19",54,[164,165,166],"Lysosomal Diseases","Gangliosidosis","GM1",[50,168,140,169,170],"Rituximab","Methylprednisolone","Prednisone",{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"intervention":50,"totalTrials":99,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":189,"PHASE4":191,"NA":193},{"trials":180,"activeCount":9},[],{"trials":182,"activeCount":9},[],{"trials":184,"activeCount":99,"soonestReadout":49},[185],{"nctId":47,"briefTitle":48,"status":91,"phases":186,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":187,"interventions":188},[53,54],[164,165,166],[50,168,140,169,170],{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[],{"trials":194,"activeCount":9},[],{"intervention":168,"totalTrials":99,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":198,"activeCount":9},[],{"trials":200,"activeCount":9},[],{"trials":202,"activeCount":99,"soonestReadout":49},[203],{"nctId":47,"briefTitle":48,"status":91,"phases":204,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":205,"interventions":206},[53,54],[164,165,166],[50,168,140,169,170],{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[],{"intervention":169,"totalTrials":99,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":225,"PHASE4":227,"NA":229},{"trials":216,"activeCount":9},[],{"trials":218,"activeCount":9},[],{"trials":220,"activeCount":99,"soonestReadout":49},[221],{"nctId":47,"briefTitle":48,"status":91,"phases":222,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":223,"interventions":224},[53,54],[164,165,166],[50,168,140,169,170],{"trials":226,"activeCount":9},[],{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[],{"intervention":170,"totalTrials":99,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":234,"activeCount":9},[],{"trials":236,"activeCount":9},[],{"trials":238,"activeCount":99,"soonestReadout":49},[239],{"nctId":47,"briefTitle":48,"status":91,"phases":240,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":241,"interventions":242},[53,54],[164,165,166],[50,168,140,169,170],{"trials":244,"activeCount":9},[],{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"intervention":250,"totalTrials":99,"cells":251},"Cysteamine",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":260,"NA":262},{"trials":253,"activeCount":9},[],{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[],{"trials":259,"activeCount":9},[],{"trials":261,"activeCount":9},[],{"trials":263,"activeCount":99},[264],{"nctId":265,"briefTitle":266,"status":91,"phases":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT00359684","Use of Cysteamine in the Treatment of Cystinosis",[],"1979-01-04",330,[271],"Cystinosis",[250],{"intervention":274,"totalTrials":99,"cells":275},"Mind-body therapy",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":277,"activeCount":9},[],{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[282],{"nctId":283,"briefTitle":284,"status":69,"phases":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT00001966","Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome",[54],"2001-01","2000-01",40,[290,291],"Ehlers-Danlos Syndrome","Pain",[274],{"trials":294,"activeCount":9},[],{"trials":296,"activeCount":9},[],{"trials":298,"activeCount":9},[],{"intervention":300,"totalTrials":99,"cells":301},"Dabrafenib Mesylate",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[308],{"nctId":309,"briefTitle":310,"status":69,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":16,"conditions":314,"interventions":316},"NCT02281760","Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease",[54],"2018-08-29","2014-11-01",[315],"BRAF V600E Mutation",[300,317],"Trametinib Dimethyl Sulfoxide",{"trials":319,"activeCount":9},[],{"trials":321,"activeCount":9},[],{"trials":323,"activeCount":9},[],{"intervention":317,"totalTrials":99,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":327,"activeCount":9},[],{"trials":329,"activeCount":9},[],{"trials":331,"activeCount":9},[332],{"nctId":309,"briefTitle":310,"status":69,"phases":333,"primaryCompletion":312,"completion":312,"start":313,"enrollment":16,"conditions":334,"interventions":335},[54],[315],[300,317],{"trials":337,"activeCount":9},[],{"trials":339,"activeCount":9},[],{"trials":341,"activeCount":9},[],{"intervention":343,"totalTrials":99,"cells":344},"Losartan",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":346,"activeCount":9},[],{"trials":348,"activeCount":9},[],{"trials":350,"activeCount":9},[351],{"nctId":352,"briefTitle":353,"status":354,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":60,"conditions":358,"interventions":364},"NCT00467831","Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome","TERMINATED",[53,54],"2012-11","2007-04",[359,360,361,362,363],"Hermansky-Pudlak Syndrome (HPS)","Pulmonary Fibrosis","Oculocutaneous Albinism","Platelet Storage Pool Deficiency","Metabolic Disease",[343,365,366,367,368],"Zileuton","N-Acetylcysteine","Pravastatin","Erythromycin",{"trials":370,"activeCount":9},[],{"trials":372,"activeCount":9},[],{"trials":374,"activeCount":9},[],{"intervention":365,"totalTrials":99,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":378,"activeCount":9},[],{"trials":380,"activeCount":9},[],{"trials":382,"activeCount":9},[383],{"nctId":352,"briefTitle":353,"status":354,"phases":384,"primaryCompletion":356,"completion":356,"start":357,"enrollment":60,"conditions":385,"interventions":386},[53,54],[359,360,361,362,363],[343,365,366,367,368],{"trials":388,"activeCount":9},[],{"trials":390,"activeCount":9},[],{"trials":392,"activeCount":9},[],{"intervention":366,"totalTrials":99,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":396,"activeCount":9},[],{"trials":398,"activeCount":9},[],{"trials":400,"activeCount":9},[401],{"nctId":352,"briefTitle":353,"status":354,"phases":402,"primaryCompletion":356,"completion":356,"start":357,"enrollment":60,"conditions":403,"interventions":404},[53,54],[359,360,361,362,363],[343,365,366,367,368],{"trials":406,"activeCount":9},[],{"trials":408,"activeCount":9},[],{"trials":410,"activeCount":9},[],{"intervention":367,"totalTrials":99,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":414,"activeCount":9},[],{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[419],{"nctId":352,"briefTitle":353,"status":354,"phases":420,"primaryCompletion":356,"completion":356,"start":357,"enrollment":60,"conditions":421,"interventions":422},[53,54],[359,360,361,362,363],[343,365,366,367,368],{"trials":424,"activeCount":9},[],{"trials":426,"activeCount":9},[],{"trials":428,"activeCount":9},[],{"intervention":368,"totalTrials":99,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":432,"activeCount":9},[],{"trials":434,"activeCount":9},[],{"trials":436,"activeCount":9},[437],{"nctId":352,"briefTitle":353,"status":354,"phases":438,"primaryCompletion":356,"completion":356,"start":357,"enrollment":60,"conditions":439,"interventions":440},[53,54],[359,360,361,362,363],[343,365,366,367,368],{"trials":442,"activeCount":9},[],{"trials":444,"activeCount":9},[],{"trials":446,"activeCount":9},[],{"intervention":448,"totalTrials":99,"cells":449},"EPI-743",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":451,"activeCount":9},[],{"trials":453,"activeCount":9},[],{"trials":455,"activeCount":9},[456],{"nctId":457,"briefTitle":458,"status":69,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":467},"NCT01642056","EPI-743 for Metabolism or Mitochondrial Disorders",[53,54],"2019-09-24","2012-09-01",20,[464,465,466],"Mitochondrial Disease","Neurology","Myopathy",[448],{"trials":469,"activeCount":9},[],{"trials":471,"activeCount":9},[],{"trials":473,"activeCount":9},[],{"intervention":475,"totalTrials":99,"cells":476},"Nitisinone",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":492,"PHASE4":494,"NA":496},{"trials":478,"activeCount":9},[],{"trials":480,"activeCount":9},[],{"trials":482,"activeCount":9},[483],{"nctId":484,"briefTitle":485,"status":69,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":288,"conditions":489,"interventions":491},"NCT00107783","Long-Term Study of Nitisinone to Treat Alkaptonuria",[54],"2009-04","2005-01",[490],"Alkaptonuria",[475],{"trials":493,"activeCount":9},[],{"trials":495,"activeCount":9},[],{"trials":497,"activeCount":9},[],{"intervention":499,"totalTrials":99,"cells":500},"rh Growth Hormone",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":502,"activeCount":9},[],{"trials":504,"activeCount":9},[],{"trials":506,"activeCount":9},[507],{"nctId":508,"briefTitle":509,"status":510,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":9,"conditions":514,"interventions":515},"NCT02124070","Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis","WITHDRAWN",[53,54],"2015-11-06","2014-03-26",[271,466],[499],{"trials":517,"activeCount":9},[],{"trials":519,"activeCount":9},[],{"trials":521,"activeCount":9},[],{"intervention":523,"totalTrials":99,"cells":524},"Immune Globulin",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":526,"activeCount":9},[],{"trials":528,"activeCount":9},[529],{"nctId":530,"briefTitle":531,"status":69,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":30,"conditions":535,"interventions":537},"NCT00195637","Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy",[53],"2006-07-03","2005-09-16",[536],"Hereditary Inclusion Body Myopathy",[523],{"trials":539,"activeCount":9},[],{"trials":541,"activeCount":9},[],{"trials":543,"activeCount":9},[],{"trials":545,"activeCount":9},[],{"intervention":547,"totalTrials":99,"cells":548},"CD34+ cells transduced with ADA retrovir",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":550,"activeCount":9},[],{"trials":552,"activeCount":9},[553],{"nctId":554,"briefTitle":555,"status":69,"phases":556,"completion":557,"start":558,"enrollment":11,"conditions":559,"interventions":561},"NCT00018018","Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency",[53],"2014-09-17","2001-06-20",[560],"Severe Combined Immunodeficiency Syndrome",[547],{"trials":563,"activeCount":9},[],{"trials":565,"activeCount":9},[],{"trials":567,"activeCount":9},[],{"trials":569,"activeCount":9},[],{"intervention":571,"totalTrials":99,"cells":572},"dTR Melatonin",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":574,"activeCount":9},[],{"trials":576,"activeCount":9},[577],{"nctId":578,"briefTitle":579,"status":69,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":590},"NCT00506259","Treatment Strategies for Children With Smith-Magenis Syndrome",[53],"2018-05-22","2007-07-17",23,[585,586,587,588,589],"Developmental Delay Disorders","Chromosome Deletion","Mental Retardation","Sleep Disorders, Circadian Rhythm","Self Injurious Behavior",[571,591],"Melatonin CR",{"trials":593,"activeCount":9},[],{"trials":595,"activeCount":9},[],{"trials":597,"activeCount":9},[],{"trials":599,"activeCount":9},[],{"intervention":591,"totalTrials":99,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":603,"activeCount":9},[],{"trials":605,"activeCount":9},[606],{"nctId":578,"briefTitle":579,"status":69,"phases":607,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":608,"interventions":609},[53],[585,586,587,588,589],[571,591],{"trials":611,"activeCount":9},[],{"trials":613,"activeCount":9},[],{"trials":615,"activeCount":9},[],{"trials":617,"activeCount":9},[],{"intervention":619,"totalTrials":99,"cells":620},"Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":622,"activeCount":9},[],{"trials":624,"activeCount":9},[625],{"nctId":626,"briefTitle":627,"status":69,"phases":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":636},"NCT00001535","Twins Study of Gene Therapy for HIV Infection",[53],"2002-03","1996-03",48,[633,634,635],"Acquired Immunodeficiency Syndrome","HIV Infection","Kaposi's Sarcoma",[619],{"trials":638,"activeCount":9},[],{"trials":640,"activeCount":9},[],{"trials":642,"activeCount":9},[],{"trials":644,"activeCount":9},[],{"intervention":646,"totalTrials":99,"cells":647},"Lentiviral Gene Transfer",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":649,"activeCount":9},[],{"trials":651,"activeCount":9},[652],{"nctId":653,"briefTitle":654,"status":69,"phases":655,"primaryCompletion":656,"completion":657,"start":656,"enrollment":99,"conditions":658,"interventions":661},"NCT02022696","Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector",[53],"2013-12-16","2017-09-21",[659,660],"Adenosine Deaminase Deficiency","ADA-SCID",[646],{"trials":663,"activeCount":9},[],{"trials":665,"activeCount":9},[],{"trials":667,"activeCount":9},[],{"trials":669,"activeCount":9},[],{"intervention":671,"totalTrials":99,"cells":672},"adenovirus RSV-TK",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":674,"activeCount":9},[],{"trials":676,"activeCount":9},[677],{"nctId":678,"briefTitle":679,"status":69,"phases":680,"start":681,"conditions":682,"interventions":684},"NCT00005057","Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma",[53],"2000-03",[683],"Melanoma (Skin)",[671,685],"ganciclovir",{"trials":687,"activeCount":9},[],{"trials":689,"activeCount":9},[],{"trials":691,"activeCount":9},[],{"trials":693,"activeCount":9},[],{"intervention":685,"totalTrials":99,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":9},[],{"trials":699,"activeCount":9},[700],{"nctId":678,"briefTitle":679,"status":69,"phases":701,"start":681,"conditions":702,"interventions":703},[53],[683],[671,685],{"trials":705,"activeCount":9},[],{"trials":707,"activeCount":9},[],{"trials":709,"activeCount":9},[],{"trials":711,"activeCount":9},[],{"intervention":713,"totalTrials":99,"cells":714},"ADA PBSC",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":716,"activeCount":9},[],{"trials":718,"activeCount":9},[],{"trials":720,"activeCount":9},[],{"trials":722,"activeCount":9},[],{"trials":724,"activeCount":9},[],{"trials":726,"activeCount":9},[727],{"nctId":728,"briefTitle":729,"status":69,"phases":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT00001255","Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study",[],"2002-07","1990-09",10,[735],"Severe Combined Immunodeficiency",[713,737,738],"ADA Umbilical Cord Blood Cells","Transduced Lymphocytes",{"intervention":737,"totalTrials":99,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":742,"activeCount":9},[],{"trials":744,"activeCount":9},[],{"trials":746,"activeCount":9},[],{"trials":748,"activeCount":9},[],{"trials":750,"activeCount":9},[],{"trials":752,"activeCount":9},[753],{"nctId":728,"briefTitle":729,"status":69,"phases":754,"completion":731,"start":732,"enrollment":733,"conditions":755,"interventions":756},[],[735],[713,737,738],{"intervention":738,"totalTrials":99,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":760,"activeCount":9},[],{"trials":762,"activeCount":9},[],{"trials":764,"activeCount":9},[],{"trials":766,"activeCount":9},[],{"trials":768,"activeCount":9},[],{"trials":770,"activeCount":9},[771],{"nctId":728,"briefTitle":729,"status":69,"phases":772,"completion":731,"start":732,"enrollment":733,"conditions":773,"interventions":774},[],[735],[713,737,738],{"intervention":776,"totalTrials":99,"cells":777},"15-0 H20",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":779,"activeCount":9},[],{"trials":781,"activeCount":9},[],{"trials":783,"activeCount":9},[],{"trials":785,"activeCount":9},[],{"trials":787,"activeCount":9},[],{"trials":789,"activeCount":9},[790],{"nctId":791,"briefTitle":792,"status":69,"phases":793,"start":794,"enrollment":795,"conditions":796,"interventions":799},"NCT00302146","Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations",[],"2006-05-23",64,[797,798],"Parkinson Disease","Gaucher Disease",[776]]